Skip to main content
Erschienen in: Breast Cancer 1/2011

01.01.2011 | Original Article

Rates of pathological underestimation for 9 and 12 gauge breast needle core biopsies at surgical excision

verfasst von: Stamatia Destounis, Melissa N. Skolny, Renee Morgan, Andrea Arieno, Philip F. Murphy, Patricia Somerville, Posy Seifert, Wende Young

Erschienen in: Breast Cancer | Ausgabe 1/2011

Einloggen, um Zugang zu erhalten

Abstract

Background

The clinical implementation of needle core biopsies has given radiologists an invaluable tool for the diagnostic evaluation of suspicious breast lesions. Despite improvements made to the technology of breast biopsy, the underestimation of disease in tissue samples retrieved continues. This can be attributed to many factors, including variability between different needle gauges. This study was undertaken to assess the pathological underestimation for 9 and 12 gauge breast needle core biopsies at surgical excision.

Materials and methods

A retrospective review of image-guided consecutive core needle biopsies performed from 2003 to 2006 yielded a total of 1,201 needle core biopsies: 837 twelve gauge and 364 nine gauge. Further analysis was completed to distinguish needle biopsies whose pathological outcome was underestimated at core needle biopsy when compared to their subsequent surgical excision. Ninety-seven lesions in 88 patients were reviewed and comprise the study cohort.

Results

Underestimation was found in 97 needle core procedures in 88 patients. Of the 97, 67 were performed with 12 gauge vacuum-assisted biopsy devices and 30 with 9 gauge vacuum-assisted biopsy devices, resulting in an underestimation rate of 8.00 and 8.24% for 12 gauge and 9 gauge, respectively. The difference in underestimation rate was not statistically significant per Pearson’s chi squared test (P = 0.8898).

Conclusion

In this analysis, the underestimation of needle biopsy results with surgical pathology was found to be 8.00% for the 12 gauge group and 8.24% for the 9 gauge group. These results support our current clinical practice of utilizing either needle gauge.
Literatur
1.
Zurück zum Zitat Liberman L, Bracero N, Vuolo M, Dershaw DD, Morris EA, Abramson AF, et al. Percutaneous large-core biopsy of papillary breast lesions. AJR Am J Roentgenol. 1999;172:331–7.PubMed Liberman L, Bracero N, Vuolo M, Dershaw DD, Morris EA, Abramson AF, et al. Percutaneous large-core biopsy of papillary breast lesions. AJR Am J Roentgenol. 1999;172:331–7.PubMed
2.
Zurück zum Zitat Schueller G, Jaromi S, Ponhold L, Fuchsjaeger M, Memarsadeghi M, Rudas M, et al. US-guided 14-gauge core-needle breast biopsy: results of a validation study in 1352 cases. Radiology. 2008;248:406–13.CrossRefPubMed Schueller G, Jaromi S, Ponhold L, Fuchsjaeger M, Memarsadeghi M, Rudas M, et al. US-guided 14-gauge core-needle breast biopsy: results of a validation study in 1352 cases. Radiology. 2008;248:406–13.CrossRefPubMed
3.
Zurück zum Zitat Youk JH, Kim EK, Kim MJ, Oh KK. Sonographically guided 14-gauge core needle biopsy of breast masses: a review of 2,420 cases with long-term follow-up. AJR Am J Roentgenol. 2008;190:202–7.CrossRefPubMed Youk JH, Kim EK, Kim MJ, Oh KK. Sonographically guided 14-gauge core needle biopsy of breast masses: a review of 2,420 cases with long-term follow-up. AJR Am J Roentgenol. 2008;190:202–7.CrossRefPubMed
4.
Zurück zum Zitat Burak WE, Owens KE, Tighe MB, Kemp L, Dinges SA, Hitchcick C, et al. Vacuum-assisted stereotactic breast biopsy. Arch Surg. 2000;135:700–3.CrossRefPubMed Burak WE, Owens KE, Tighe MB, Kemp L, Dinges SA, Hitchcick C, et al. Vacuum-assisted stereotactic breast biopsy. Arch Surg. 2000;135:700–3.CrossRefPubMed
5.
Zurück zum Zitat Rakha EA, Ellis IO. An overview of assessment of prognostic and predictive factors in breast cancer needle core biopsy specimens. J Clin Pathol. 2007;60:1300–6.CrossRefPubMed Rakha EA, Ellis IO. An overview of assessment of prognostic and predictive factors in breast cancer needle core biopsy specimens. J Clin Pathol. 2007;60:1300–6.CrossRefPubMed
6.
Zurück zum Zitat Margolin FR, Leung JW, Jacobs RP, Denny SR. Percutaneous imaging-guided core breast biopsy; 5 years’ experience in a community hospital. AJR Am J Roentgenol. 2001;177:559–64.PubMed Margolin FR, Leung JW, Jacobs RP, Denny SR. Percutaneous imaging-guided core breast biopsy; 5 years’ experience in a community hospital. AJR Am J Roentgenol. 2001;177:559–64.PubMed
7.
Zurück zum Zitat Heywang-Kobrunner SH, Schaumloffel U, Viehweg P, Hofer H, Buchmann J, Lampe D. Minimally invasive stereotaxic vacuum core breast biopsy. Eur Radiol. 1998;8:377–85.CrossRefPubMed Heywang-Kobrunner SH, Schaumloffel U, Viehweg P, Hofer H, Buchmann J, Lampe D. Minimally invasive stereotaxic vacuum core breast biopsy. Eur Radiol. 1998;8:377–85.CrossRefPubMed
8.
Zurück zum Zitat Brem RF, Schoonjans JM, Goodman SN, Nolton A, Askin FB, Gatewood OM. Nonpalpable breast cancer: percutaneous diagnosis with 11- and 8-gauge stereotactic vacuum-assisted biopsy devices. Radiology. 2001;219:793–6.PubMed Brem RF, Schoonjans JM, Goodman SN, Nolton A, Askin FB, Gatewood OM. Nonpalpable breast cancer: percutaneous diagnosis with 11- and 8-gauge stereotactic vacuum-assisted biopsy devices. Radiology. 2001;219:793–6.PubMed
9.
Zurück zum Zitat Lourenco AP, Mainiero MB, Lazarus E, Giri D, Schepps B. Stereotactic breast biopsy: comparison of histologic underestimation rates with 11- and 9- gauge vacuum-assisted breast biopsy. AJR Am J Roentgenol. 2007;189:W275–9.CrossRefPubMed Lourenco AP, Mainiero MB, Lazarus E, Giri D, Schepps B. Stereotactic breast biopsy: comparison of histologic underestimation rates with 11- and 9- gauge vacuum-assisted breast biopsy. AJR Am J Roentgenol. 2007;189:W275–9.CrossRefPubMed
10.
Zurück zum Zitat Darling ML, Smith DN, Lester SC, Kaelin C, Selland DG, Denison CM, et al. Atypical ductal hyperplasia and ductal carcinoma in situ as revealed by large-core needle breast biopsy: results of surgical excision. AJR Am J Roentgenol. 2000;175:1341–6.PubMed Darling ML, Smith DN, Lester SC, Kaelin C, Selland DG, Denison CM, et al. Atypical ductal hyperplasia and ductal carcinoma in situ as revealed by large-core needle breast biopsy: results of surgical excision. AJR Am J Roentgenol. 2000;175:1341–6.PubMed
11.
Zurück zum Zitat Jang M, Cho N, Moon WK, Park JS, Seong MH, Park IA. Underestimation of atypical ductal hyperplasia at sonographically guided core biopsy of the breast. AJR Am J Roentgenol. 2008;191:1347–51.CrossRefPubMed Jang M, Cho N, Moon WK, Park JS, Seong MH, Park IA. Underestimation of atypical ductal hyperplasia at sonographically guided core biopsy of the breast. AJR Am J Roentgenol. 2008;191:1347–51.CrossRefPubMed
12.
Zurück zum Zitat Liberman L, Hollan AE, Marjan D, Murray MP, Bartella L, Morris EA, et al. Underestimation of atypical ductal hyperplasia at MRI-guided 9-gauge vacuum-assisted breast biopsy. AJR Am J Roentgenol. 2007;188:684–90.CrossRefPubMed Liberman L, Hollan AE, Marjan D, Murray MP, Bartella L, Morris EA, et al. Underestimation of atypical ductal hyperplasia at MRI-guided 9-gauge vacuum-assisted breast biopsy. AJR Am J Roentgenol. 2007;188:684–90.CrossRefPubMed
13.
Zurück zum Zitat Jackman RJ, Burbank F, Parker SH, Evans WP, Lechner MC, Richardson TR, et al. Stereotactic breast biopsy of nonpalpable lesions: determinants of ductal carcinoma in situ underestimation rates. Radiology. 2001;218:497–502.PubMed Jackman RJ, Burbank F, Parker SH, Evans WP, Lechner MC, Richardson TR, et al. Stereotactic breast biopsy of nonpalpable lesions: determinants of ductal carcinoma in situ underestimation rates. Radiology. 2001;218:497–502.PubMed
14.
Zurück zum Zitat Jackman RJ, Burbank F, Parker SH, Phil EW, Lechner MC, Richardson TR, et al. Atypical ductal hyperplasia diagnosed at stereotactic breast biopsy: improved reliability with 14-gauge, directional, vacuum-assisted biopsy. Radiology. 1997;204:484–8. Jackman RJ, Burbank F, Parker SH, Phil EW, Lechner MC, Richardson TR, et al. Atypical ductal hyperplasia diagnosed at stereotactic breast biopsy: improved reliability with 14-gauge, directional, vacuum-assisted biopsy. Radiology. 1997;204:484–8.
15.
Zurück zum Zitat Philpotts LE, Lee CH, Horvath LJ, Lange RC, Carter D, Tocino I. Underestimation of breast cancer with 11-gauge vacuum-suction biopsy. AJR Am J Roentgenol. 2000;175:1047–50.PubMed Philpotts LE, Lee CH, Horvath LJ, Lange RC, Carter D, Tocino I. Underestimation of breast cancer with 11-gauge vacuum-suction biopsy. AJR Am J Roentgenol. 2000;175:1047–50.PubMed
16.
Zurück zum Zitat Burbank F. Stereotactic breast biopsy of atypical ductal hyperplasia and ductal carcinoma in situ lesions: improved accuracy with directional vacuum-assisted biopsy. Radiology. 1997;202:843–7.PubMed Burbank F. Stereotactic breast biopsy of atypical ductal hyperplasia and ductal carcinoma in situ lesions: improved accuracy with directional vacuum-assisted biopsy. Radiology. 1997;202:843–7.PubMed
17.
Zurück zum Zitat Philpotts LE, Shaheen NA, Carter D, Lange RC, Lee CH. Comparison of re-biopsy rates after stereotactic core needle biopsy of the breast with 11-gauge vacuum suction probe versus 14-gauge needle and automated gun. AJR Am J Roentgenol. 1998;172:683–7. Philpotts LE, Shaheen NA, Carter D, Lange RC, Lee CH. Comparison of re-biopsy rates after stereotactic core needle biopsy of the breast with 11-gauge vacuum suction probe versus 14-gauge needle and automated gun. AJR Am J Roentgenol. 1998;172:683–7.
18.
Zurück zum Zitat Philpotts LE, Hooley RJ, Lee CH. Comparison of automated versus vacuum-assisted biopsy methods for sonographically guided core biopsy of the breast. AJR Am J Roentgenol. 2003;180:347–51.PubMed Philpotts LE, Hooley RJ, Lee CH. Comparison of automated versus vacuum-assisted biopsy methods for sonographically guided core biopsy of the breast. AJR Am J Roentgenol. 2003;180:347–51.PubMed
Metadaten
Titel
Rates of pathological underestimation for 9 and 12 gauge breast needle core biopsies at surgical excision
verfasst von
Stamatia Destounis
Melissa N. Skolny
Renee Morgan
Andrea Arieno
Philip F. Murphy
Patricia Somerville
Posy Seifert
Wende Young
Publikationsdatum
01.01.2011
Verlag
Springer Japan
Erschienen in
Breast Cancer / Ausgabe 1/2011
Print ISSN: 1340-6868
Elektronische ISSN: 1880-4233
DOI
https://doi.org/10.1007/s12282-010-0201-1

Weitere Artikel der Ausgabe 1/2011

Breast Cancer 1/2011 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.